AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06564545 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06564545 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06564545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT06564545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT04697576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg/m2, BID, orally
Study NCT06362798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Transfers
Description: Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age.
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2/dose
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: 3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedamustine
Description: 180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Study NCT05632692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol solution
Description: Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
Study NCT05632692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Menthol solution
Description: Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
Study NCT06331117 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Multiomics profiling
Study NCT04697576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
Study NCT04697576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT04697576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: immune checkpoint inhibitor
Study NCT04906330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oncoliq: test for early breast cancer detection.
Description: Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
Study NCT06461117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Beetroot juice (8 mmol NO3-) consumption before training at 6 days
Study NCT06461117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plesabo Drink
Description: Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
Study NCT05687682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
Study NCT04922450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of SHR1210 (200mg/3weeks)
Study NCT04922450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel(260mg/m²),every 3 weeks
Study NCT04922450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin（80mg/m²）, every 3 weeks
Study NCT06060548 — intervention group
Intervention type: OTHER
Intervention: Monitoring of patients presenting with PVCs
Description: Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
Study NCT05443906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Exercise to address limitations impacting walking
Study NCT06044792 — intervention group
Intervention type: OTHER
Intervention: differences in CD4 reconstruction
Description: Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
Study NCT06472544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Grounded Intervention
Description: Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
Study NCT05193318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-assisted psychotherapy
Description: Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
Study NCT04311307 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: [6,6-2H2]glucose
Description: Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
Study NCT04311307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [6,6-2H2]glucose
Description: Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
Study NCT05910346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and counseling based on maternal role theory
Description: Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
Study NCT06048458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance with stress perfusion
Description: Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
Study NCT06048458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography
Description: CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
Study NCT06048458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal OCT angiography
Description: Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
Study NCT06048458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual microscopy (GlycoCheck)
Description: To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
Study NCT06048458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)
Description: Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
Study NCT06454656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOBILE
Description: Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback
Study NCT06129149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Care-adapted and Checklist-guided ACP intervention
Description: The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
Study NCT05626712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELZ-201 Administration
Description: Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
Study NCT05626712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Enhanced standard of care for Type 1 Diabetes treatment only.
Study NCT04392037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide plus low-dose cyclophosphamide and dexamethasone
Description: Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
Study NCT05132816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution manometry
Description: High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed.
Study NCT05439941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Study NCT06478459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK
Description: Endoscopic ultrasound-guided intratumoral CAR-NK injection once at day 0, combined with intravenous CAR-NK infusion twice at day 4 and 5
Study NCT06061757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging guidance with TEE and ICE for Left atrial appendage closure
Description: The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
Study NCT06152003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)
Description: We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
Study NCT06361836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT777101
Description: Experimental treatment
Study NCT05514288 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobariatric procedure
Description: Endoscopic sleeve gastroplasty or transoral outlet reduction
Study NCT06315374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use soft mist inhaler
Description: Only use soft mist inhaler
Study NCT06315374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use soft mist inhaler with a 3D assistive device
Description: Use soft mist inhaler with a 3D-printed assist device
Study NCT06640101 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham IMT
Description: with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted while sitting on the chair.
Study NCT06640101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target IMT (sitting on a chair)
Description: IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on a chair
Study NCT06640101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target IMT (sitting on an unstable surface)
Description: IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on an unstable surface
Study NCT06640101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
Study NCT05393128 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group (Supine Position)
Description: In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.
Study NCT05393128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Group (Right Lateral position)
Description: In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.
Study NCT05393128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Group (Left Lateral position)
Description: In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position.
Study NCT04969640 — intervention group
Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Anterior segment optical coherence tomography examination of corneas with infective keratitis
Study NCT05607615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Beta Cyclodextrin
Description: Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
Study NCT05607615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5N saline as an intravenous (IV) infusion once every 28 days
Study NCT04840004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PVT-1
Description: Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
Study NCT04825002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary multimarker sensor
Description: We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
Study NCT06640101 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
Study NCT06642727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
Study NCT06208423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPT-4
Description: OpenAI's GPT-4 large language model with chat interface.
Study NCT06377475 — intervention group
Intervention type: PROCEDURE
Intervention: Jaw relation
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.